Atenção!


O atendimento às questões referentes ao Repositório Institucional será interrompido entre os dias 20 de dezembro de 2025 a 4 de janeiro de 2026.

Pedimos a sua compreensão e aproveitamos para desejar boas festas!

Logo do repositório

Use of artificial cells as drug carriers

dc.contributor.authorEmir Diltemiz, Sibel
dc.contributor.authorTavafoghi, Maryam
dc.contributor.authorDe Barros, Natan Roberto [UNESP]
dc.contributor.authorKanada, Masamitsu
dc.contributor.authorHeinämäki, Jyrki
dc.contributor.authorContag, Christopher
dc.contributor.authorSeidlits, Stephanie K.
dc.contributor.authorAshammakhi, Nureddin
dc.contributor.institutionUniversity of California
dc.contributor.institutionEskisehir Technical University
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionMichigan State University
dc.contributor.institutionUniversity of Tartu
dc.date.accessioned2022-04-28T19:44:49Z
dc.date.available2022-04-28T19:44:49Z
dc.date.issued2021-09-21
dc.description.abstractCells are the fundamental functional units of biological systems and mimicking their size, function and complexity is a primary goal in the development of new therapeutic strategies. Recent advances in chemistry, synthetic biology and material science have enabled the development of cell membrane-based drug delivery systems (DDSs), often referred to as artificial cellsor protocells. Artificial cells can be made by removing functions from natural systems in a top-down manner, or assembly from synthetic, organic or inorganic materials, through a bottom-up approach where simple units are integrated to form more complex structures. This review covers the latest advances in the development of artificial cells as DDSs, highlighting how their designs have been inspired by natural cells or cell membranes. Advancement of artificial cell technologies has led to a set of drug carriers with effective and controlled release of a variety of therapeutics for a range of diseases, and with increasing complexity they will have a greater impact on therapeutic designs. This journal isen
dc.description.affiliationDepartment of Bioengineering Henry Samueli School of Engineering University of California, 420 Westwood Plaza, Engineering V
dc.description.affiliationDepartment of Chemistry Eskisehir Technical University
dc.description.affiliationDepartment of Bioprocess and Biotechnology Engineering São Paulo State University (UNESP) School of Pharmaceutical Sciences, São Paulo
dc.description.affiliationInstitute for Quantitative Health Science and Engineering (IQ) Department of Pharmacology and Toxicology College of Human Medicine Michigan State University
dc.description.affiliationInstitute of Pharmacy Faculty of Medicine University of Tartu, Nooruse Str. 1
dc.description.affiliationInstitute for Quantitative Health Science and Engineering (IQ) Departments of Biomedical Engineering (BME) Microbiology and Molecular Genetics Michigan State University
dc.description.affiliationInstitute for Quantitative Health Science and Engineering (IQ) Department of Biomedical Engineering (BME) Michigan State University
dc.description.affiliationUnespDepartment of Bioprocess and Biotechnology Engineering São Paulo State University (UNESP) School of Pharmaceutical Sciences, São Paulo
dc.format.extent6672-6692
dc.identifierhttp://dx.doi.org/10.1039/d1qm00717c
dc.identifier.citationMaterials Chemistry Frontiers, v. 5, n. 18, p. 6672-6692, 2021.
dc.identifier.doi10.1039/d1qm00717c
dc.identifier.issn2052-1537
dc.identifier.scopus2-s2.0-85115378920
dc.identifier.urihttp://hdl.handle.net/11449/222464
dc.language.isoeng
dc.relation.ispartofMaterials Chemistry Frontiers
dc.sourceScopus
dc.titleUse of artificial cells as drug carriersen
dc.typeResenhapt
dspace.entity.typePublication
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos